v3.25.3
Accounts Payable and Accrued Liabilities
 9 Months Ended
Sep. 30, 2025
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities
8. Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consist of the following (in thousands):
As of
September 30, 2025December 31, 2024
Accounts payable and other accrued operating expenses$79,591 $73,033 
Accrued clinical trial expenses30,730 26,068 
Accrued professional fees25,776 17,895 
Accrued technical operation expenses20,227 18,388 
Accrued compensation and employee related costs69,712 80,312 
Accrued royalty and milestones payable9,372 6,324 
Accrued interest payable— 359 
Revenue Interest Payments payable4,941 4,177 
Accrued sales allowances and related costs33,026 16,762 
Accrued French rebate payable10,049 5,988 
Contingent consideration42,500 24,700 
Development milestone shares issuable48,753 — 
Accrued milestone payment to AstraZeneca30,000 — 
Other accrued liabilities5,158 11,203 
$409,835 $285,209 
In August 2025, a development milestone in connection with the Motus acquisition was achieved. See Note 3 - Fair Value Measurements for further details. Also in August 2025, a $30.0 million milestone commitment became payable to AstraZeneca upon FDA approval of BRINSUPRI. See Note 6 - Intangibles, Net and Goodwill for further details.